Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.49 |
| ▸ | ADCY6 | O43306 | 1/20 | 0.46 |
| ▸ | ADCY3 | O60266 | 1/20 | 0.46 |
| ▸ | ADCY9 | O60503 | 1/20 | 0.46 |
| ▸ | ADCY5 | O95622 | 1/20 | 0.46 |
| ▸ | ADCY8 | P40145 | 1/20 | 0.46 |
| ▸ | ADCY7 | P51828 | 1/20 | 0.46 |
| ▸ | ADCY2 | Q08462 | 1/20 | 0.46 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.46 |
| ▸ | ADCY4 | Q8NFM4 | 1/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.44 |
| ▸ | HTR2C | P28335 | 7/20 | 0.41 |
| ▸ | HTR2B | P41595 | 6/20 | 0.41 |
| ▸ | HTR2A | P28223 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL721243 | 0.84 | DRD2 (0.41) | DRD2ADCY6ADCY3ADCY9ADCY5 | |
| SCHEMBL719739 | 0.83 | DRD2 (0.42) | DRD2ADCY6ADCY3ADCY9ADCY5 | |
| SCHEMBL719123 | 0.80 | DRD2 (0.44) | DRD2ADCY6ADCY3ADCY9ADCY5 | |
| SCHEMBL719750 | 0.78 | DRD2 (0.45) | DRD2ADCY6ADCY3ADCY9ADCY5 | |
| SCHEMBL718663 | 0.75 | CYP1A2 (0.46) | DRD2ADCY6ADCY3ADCY9ADCY5 | |
| SCHEMBL720947 | 0.75 | CHRNB2 (0.47) | DRD2ADCY6ADCY3ADCY9ADCY5 | |
| SCHEMBL11742860 | 0.74 | ADCY6 (0.56) | DRD2ADCY6ADCY3ADCY9ADCY5 | |
| SCHEMBL2309780 | 0.74 | CHRNB2 (0.53) | DRD2ADCY6ADCY3ADCY9ADCY5 | |
| SCHEMBL2307093 | 0.74 | DRD2 (0.66) | DRD2ADCY6ADCY3ADCY9ADCY5 | |
| SCHEMBL720637 | 0.73 | ADCY6 (0.50) | DRD2ADCY6ADCY3ADCY9ADCY5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053168-A1 | FUSED BENZOAZEPINES AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | TARGACEPT, INC. (US) | 2012-03-01 | — | — | US | claimed |
| WO-2010096384-A2 | FUSED BENZAZEPINES AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | TARGACEPT, INC. (US) | 2010-08-26 | — | — | WO | claimed |
| US-20120053168-A1 | FUSED BENZOAZEPINES AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | TARGACEPT, INC. (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120053168-A1 | FUSED BENZOAZEPINES AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | TARGACEPT, INC. (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120053168-A1 | FUSED BENZOAZEPINES AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | TARGACEPT, INC. (US) | 2012-03-01 | — | — | US | disclosed |
| WO-2010096384-A2 | FUSED BENZAZEPINES AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | TARGACEPT, INC. (US) | 2010-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053168-A1 | FUSED BENZOAZEPINES AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA2, CHRNA5, CHRNA10 | DRD2 282/4885ADCY6 1033/4885ADCY3 724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.